SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis

ABSTRACT SQ109, a 1,2-diamine related to ethambutol, is currently in clinical trials for the treatment of tuberculosis, but its mode of action remains unclear. Here, we demonstrate that SQ109 disrupts cell wall assembly, as evidenced by macromolecular incorporation assays and ultrastructural analyses. SQ109 interferes with the assembly of mycolic acids into the cell wall core of Mycobacterium tuberculosis, as bacilli exposed to SQ109 show immediate inhibition of trehalose dimycolate (TDM) production and fail to attach mycolates to the cell wall arabinogalactan. These effects were not due to inhibition of mycolate synthesis, since total mycolate levels were unaffected, but instead resulted in the accumulation of trehalose monomycolate (TMM), the precursor of TDM and cell wall mycolates. In vitro assays using purified enzymes showed that this was not due to inhibition of the secreted Ag85 mycolyltransferases. We were unable to achieve spontaneous generation of SQ109-resistant mutants; however, analogs of this compound that resulted in similar shutdown of TDM synthesis with concomitant TMM accumulation were used to spontaneously generate resistant mutants that were also cross-resistant to SQ109. Whole-genome sequencing of these mutants showed that these all had mutations in the essential mmpL3 gene, which encodes a transmembrane transporter. Our results suggest that MmpL3 is the target of SQ109 and that MmpL3 is a transporter of mycobacterial TMM.

[1]  Jun Liu,et al.  Cell Wall Structure of a Mutant of Mycobacterium smegmatis Defective in the Biosynthesis of Mycolic Acids* , 2000, The Journal of Biological Chemistry.

[2]  Anthony D. Harries,et al.  Treatment of tuberculosis: guidelines for national programmes. Second edition. , 1997 .

[3]  Marianne Terrot,et al.  Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. , 2003, Journal of combinatorial chemistry.

[4]  Gilla Kaplan,et al.  The Role of MmpL8 in Sulfatide Biogenesis and Virulence of Mycobacterium tuberculosis* , 2004, Journal of Biological Chemistry.

[5]  A. Lees,et al.  Ethambutol in the retreatment of chronic pulmonary tuberculosis. , 1970, British journal of diseases of the chest.

[6]  P. Draper,et al.  The outer parts of the mycobacterial envelope as permeability barriers. , 1998, Frontiers in bioscience : a journal and virtual library.

[7]  R. Newman,et al.  Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials. , 1973, The American review of respiratory disease.

[8]  J. Cox,et al.  Interaction between Polyketide Synthase and Transporter Suggests Coupled Synthesis and Export of Virulence Lipid in M. tuberculosis , 2005, PLoS pathogens.

[9]  L. Jia,et al.  Interspecies pharmacokinetics and in vitro metabolism of SQ109 , 2006, British journal of pharmacology.

[10]  J. Blanchard,et al.  Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis , 2009, Science.

[11]  G. Besra,et al.  Identification of the apparent carrier in mycolic acid synthesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Brennan,et al.  Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis. , 2001, Glycobiology.

[13]  K. Takayama,et al.  Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis , 1989, Antimicrobial Agents and Chemotherapy.

[14]  M. Daffé,et al.  New insights into the biogenesis of the cell envelope of corynebacteria: identification and functional characterization of five new mycoloyltransferase genes in Corynebacterium glutamicum. , 2003, FEMS microbiology letters.

[15]  J. Mcclatchy.  Mechanism of Action of Isoniazid on Mycobacterium bovis Strain BCG , 1971, Infection and immunity.

[16]  Mohamed Chami,et al.  Direct Visualization of the Outer Membrane of Mycobacteria and Corynebacteria in Their Native State , 2008, Journal of bacteriology.

[17]  I. Földes,et al.  Incorporation of thymine, thymidine, adenine and uracil into nucleic acids of Mycobacterium phlei and its phage. , 1983, Annales de microbiologie.

[18]  B. Wolucka,et al.  Biosynthesis of D‐arabinose in mycobacteria – a novel bacterial pathway with implications for antimycobacterial therapy , 2008, The FEBS journal.

[19]  P. Klatser,et al.  Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance , 2009, The Journal of antimicrobial chemotherapy.

[20]  Andrew Leis,et al.  Disclosure of the mycobacterial outer membrane: Cryo-electron tomography and vitreous sections reveal the lipid bilayer structure , 2008, Proceedings of the National Academy of Sciences.

[21]  T. Myers,et al.  The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism , 2004, Journal of Biological Chemistry.

[22]  M. Daffé,et al.  The envelope layers of mycobacteria with reference to their pathogenicity. , 1998, Advances in microbial physiology.

[23]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[24]  Gurdyal S Besra,et al.  The methyl-branched fortifications of Mycobacterium tuberculosis. , 2002, Chemistry & biology.

[25]  Digambar Behera,et al.  Global tuberculosis control 2010 , 2012 .

[26]  C. E. Barry,et al.  Analysis of the Lipids of Mycobacterium tuberculosis. , 2001, Methods in molecular medicine.

[27]  J. Blanchard,et al.  The chemical biology of new drugs in the development for tuberculosis. , 2010, Current opinion in chemical biology.

[28]  G. Besra,et al.  Pathway to Synthesis and Processing of Mycolic Acids in Mycobacterium tuberculosis , 2005, Clinical Microbiology Reviews.

[29]  H. Nikaido,et al.  Mechanisms of RND multidrug efflux pumps. , 2009, Biochimica et biophysica acta.

[30]  M. Daffé,et al.  Transport assays and permeability in pathogenic mycobacteria. , 2009, Methods in molecular biology.

[31]  D. Crick,et al.  Targeting the formation of the cell wall core of M. tuberculosis. , 2007, Infectious disorders drug targets.

[32]  L. Via,et al.  Mutations in gidB Confer Low-Level Streptomycin Resistance in Mycobacterium tuberculosis , 2011, Antimicrobial Agents and Chemotherapy.

[33]  B. Gicquel,et al.  Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope , 1999, Molecular microbiology.

[34]  Sung-Hou Kim,et al.  Physical organization of lipids in the cell wall of Mycobacterium chelonae , 1993, Molecular microbiology.

[35]  R. Lange,et al.  The targets of currently used antibacterial agents: lessons for drug discovery. , 2007, Current pharmaceutical design.

[36]  J. Liu,et al.  Mycolic Acid Structure Determines the Fluidity of the Mycobacterial Cell Wall* , 1996, The Journal of Biological Chemistry.

[37]  M. Hazbón,et al.  The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol , 2005, Molecular microbiology.

[38]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[39]  G. Besra,et al.  Ligation of arabinogalactan to peptidoglycan in the cell wall of Mycobacterium smegmatis requires concomitant synthesis of the two wall polymers. , 2002, Microbiology.

[40]  K. Takayama,et al.  Effect of Isoniazid on the In Vivo Mycolic Acid Synthesis, Cell Growth, and Viability of Mycobacterium tuberculosis , 1972, Antimicrobial Agents and Chemotherapy.

[41]  R. Slayden,et al.  Mycolic acids: structure, biosynthesis and physiological functions. , 1998, Progress in lipid research.

[42]  T. Weisbrod,et al.  Characterization of the Mycobacterium tuberculosis iniBAC Promoter, a Promoter That Responds to Cell Wall Biosynthesis Inhibition , 2000, Journal of bacteriology.

[43]  C. Nacy,et al.  Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs , 2007, Antimicrobial Agents and Chemotherapy.

[44]  M. Daffé,et al.  Characterization of the in vivo acceptors of the mycoloyl residues transferred by the corynebacterial PS1 and the related mycobacterial antigens 85 , 2000, Molecular microbiology.

[45]  Ping Chen,et al.  Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. , 2005, The Journal of antimicrobial chemotherapy.

[46]  Keriann M. Backus,et al.  Mycolic Acid/Cyclopropane Fatty Acid/Fatty Acid Biosynthesis and Health Relations , 2010 .

[47]  L. Jia,et al.  Pharmacodynamics and pharmacokinetics of SQ109, a new diamine‐based antitubercular drug , 2005, British journal of pharmacology.

[48]  P. Brennan,et al.  Chapter 2: Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis. , 2009, Advances in applied microbiology.

[49]  C. Elkins,et al.  Substrate Specificity of the RND-Type Multidrug Efflux Pumps AcrB and AcrD of Escherichia coli Is Determined Predominately by Two Large Periplasmic Loops , 2002, Journal of bacteriology.

[50]  E. Rubin,et al.  Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.

[51]  Karl W. Broman,et al.  A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Jelliffe,et al.  Pharmacokinetics of ethambutol in children and adults with tuberculosis. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[53]  G. Besra,et al.  The M. tuberculosis antigen 85 complex and mycolyltransferase activity , 2002, Letters in applied microbiology.

[54]  G. Besra,et al.  Biogenesis of the mycobacterial cell wall and the site of action of ethambutol , 1995, Antimicrobial agents and chemotherapy.

[55]  D. Schomburg,et al.  The Crucial Role of Trehalose and Structurally Related Oligosaccharides in the Biosynthesis and Transfer of Mycolic Acids in Corynebacterineae* , 2005, Journal of Biological Chemistry.

[56]  B. G. Davis,et al.  Uptake of unnatural trehalose analogs as a reporter for Mycobacterium tuberculosis. , 2011, Nature chemical biology.

[57]  R. Shepherd,et al.  STRUCTURE‐ACTIVITY STUDIES LEADING TO ETHAMBUTOL, A NEW TYPE OF ANTITUBERCULOUS COMPOUND * , 1966, Annals of the New York Academy of Sciences.

[58]  B. Gicquel,et al.  Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. , 2001, The Journal of biological chemistry.

[59]  P. Peters,et al.  Direct Visualization by Cryo-EM of the Mycobacterial Capsular Layer: A Labile Structure Containing ESX-1-Secreted Proteins , 2010, PLoS pathogens.

[60]  Carolyn R Bertozzi,et al.  MmpL8 is required for sulfolipid-1 biosynthesis and Mycobacterium tuberculosis virulence , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[61]  E. Fischer,et al.  Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium , 1998, Molecular microbiology.

[62]  L. Heifets,et al.  Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosis. , 1991, The American review of respiratory disease.

[63]  D. Minnikin,et al.  Loss of a Mycobacterial Gene Encoding a Reductase Leads to an Altered Cell Wall Containing β-oxo- Mycolic Acid Analogs and Accumulation of Ketones , 2008, Chemistry & biology.

[64]  H. Nikaido,et al.  Fluidity of the lipid domain of cell wall from Mycobacterium chelonae. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[65]  G. Besra,et al.  Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. , 1997, Science.

[66]  R. Reynolds,et al.  Programs to facilitate tuberculosis drug discovery: the tuberculosis antimicrobial acquisition and coordinating facility. , 2007, Infectious disorders drug targets.

[67]  Stewart T. Cole,et al.  Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.

[68]  M. Reed,et al.  Contribution of the Mycobacterium tuberculosis MmpL Protein Family to Virulence and Drug Resistance , 2005, Infection and Immunity.

[69]  L. Jia,et al.  Pharmacoproteomic Effects of Isoniazid, Ethambutol, and N-Geranyl-N′-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv , 2005, Journal of Pharmacology and Experimental Therapeutics.

[70]  H. Nikaido,et al.  The envelope of mycobacteria. , 1995, Annual review of biochemistry.

[71]  Brendan Prideaux,et al.  High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. , 2011, Analytical chemistry.

[72]  P. Brennan.  Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. , 2003, Tuberculosis.

[73]  Catherine Vilchèze,et al.  The mechanism of isoniazid killing: clarity through the scope of genetics. , 2007, Annual review of microbiology.